论文部分内容阅读
美国的ＮｅｗＢｉｏｔｉｃｓ公司正在探索对治疗抗药性越来越增加的原因 ,为癌和感染症治疗新药的发现与开发寻求新的途径。该公司正在开发 2种称之为ＥＣＴＡ(酶催化治疗药技术 )和ＤＭ(双微染色体技术 )的平台技术。ＥＣＴＡ技术是依据一些酶在抗药性细胞内 ,例如肿瘤过度表
NewBiotics in the United States is exploring the reasons for the increasing drug resistance and finding new ways for the discovery and development of new drugs for the treatment of cancer and infectious diseases. The company is developing two platform technologies called ECTA (Enzyme-Catalyzed Therapeutic Drug Technology) and DM (Dual Micro-Chromosome Technology). ECTA technology is based on a number of enzymes in drug-resistant cells, such as tumor overexpression